Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer

NCT04149444 is registered in ClinicalTrials.gov with AHS Cancer Control Alberta as lead sponsor.

NCT NCT04149444
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04149444 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer
Lead sponsor
AHS Cancer Control Alberta
Phase
Phase 2
Overall status
Withdrawn
Start date
February 29, 2020
Completion date
June 9, 2020
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic triple negative breast cancer